Skip to main content
. 2020 Aug 7;13:111. doi: 10.3389/fnmol.2020.00111

Figure 5.

Figure 5

The P2X7R antagonist, brilliant blue G (BBG), prevented alterations associated with neuroinflammation in the striatum and substantia nigra of hemiparkinsonian rats suffering from L-DOPA-induced dyskinesia. Rats were either sham-operated or challenged with 6-OHDA (unilateral striatal injection of 18 μg/3 μl) and later treated either with saline or L-DOPA (30 mg/kg, v.o. daily) or L-DOPA plus BBG (45 mg/kg, IP daily, 30 min before L-DOPA), before being sacrificed for preparation of either coronal brain sections (50 μm thick) or extracts from the striatum or substantia nigra for Western blot analysis. (A,B) The average immunohistochemical density of cyclooxygenase-2 (COX-2) in the striatum (A) and nigra (B); bar values are mean ± SEM of four rats per group; *p < 0.05 vs. 6-OHDA, **p < 0.05 vs. 6-OHDA + L-DOPA, using an ANOVA followed by a Tukey’s test. (C,D) Immunodensity of interleukin-1β determined by Western blot analysis in the striatum (C) and nigra (D); bar values are mean ± SEM of four rats per group; *p < 0.05 vs. 6-OHDA, **p < 0.05 vs. 6-OHDA + L-DOPA, using an ANOVA followed by a Tukey’s test. Scale bar: 100 μm.